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Abstract
Background: Although tolvaptan treatment improves hyponatremia, only few studies have investigated whether
tolvaptan actually benefits the survival of cirrhotic patients. This study evaluated the impact of tolvaptan on six-
month survival of decompensated cirrhotic patients with and without hyponatremia.
Methods: Two hundred forty-nine decompensated cirrhotic patients with or without hyponatremia were enrolled
in a multicenter cohort study. Patients were divided into two groups according to receiving either tolvaptan or
placebo treatment for 7-day. Subsequently, the patients were followed up for 6 months.
Results: Two hundred thirty patients, including 98 with hyponatremia (tolvaptan vs. placebo: 69 vs. 29) finished the
study. Tolvaptan did not alter serum sodium levels and survival outcome of decompensated cirrhotic patients
without hyponatremia. However, tolvaptan treatment remarkably improved serum sodium levels and six-month
survival in patients with hyponatremia. Following tolvaptan treatment, serum sodium levels were restored to
normal in 63.8% of patients, whereas in patients receiving placebo, only 36.2% showed the same effect (P < 0.05).
Compared to a six-month survival rate of 68.97% in patients receiving placebo, the survival rate in tolvapatan-
treated patients was 89.94% (P < 0.05). Furthermore, six-month survival rate in the tolvaptan-treated hyponatremia
patients with resolved serum sodium was 81.32%, whereas the survival in those with unresolved serum sodium was
only 24% (P < 0.05).
Conclusions: Tolvaptan improves short term survival in most decompensated cirrhotic hyponatremia patients with
resolved serum sodium.
Trials registration: Clinical trial one: ClinicalTrials.gov ID:NCT00664014, Registered on April 14, 2008.
Clinical trial two: ClinicalTrials.gov ID:NCT01349335, Registered on March 5, 2010.
Clinical trial three: ClinicalTrials.gov ID:NCT01349348, Registered on May 4, 2011.
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Background
Cirrhotic patients with ascites and hyponatremia have a
poor quality of life and high mortality [1]. One-year survival
rate in these patients is less than 60% [2]. Development of
ascites with or without hyponatremia is associated with
multiple pathophysiological alteration, i.e. renal water and
sodium retention, hyperdynamic cardiovascular dysfunction
secondary to arterial splanchnic vasodilation, activation of
the renin-aldosterone system, and increased aldosterone
and vasopressin levels in the peripheral circulation [3, 4].
Classic diuretics such as furosemide and aldosterone
antagonists spironolactone improve water retention and
edema, but exacerbate hyponatremia in cirrhotic pa-
tients [5]. Distinct from the classic diuretics, tolvaptan, a
highly selective vasopressin V2 antagonist, effectively
improves levels of serum sodium by increasing the ex-
cretion of electrolyte-free water without altering total
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level of electrolyte excretion [6]. Previous clinical studies
showed that tolvaptan improved serum sodium levels in
cirrhotic patients with ascites [6–8]. However, few stud-
ies to date have assessed whether tolvaptan treatment
improves the survival of cirrhotic patients when hypona-
tremia is resolved [9]. The current cohort study ad-
dresses this question by following up cirrhotic patients
for six months after tolvaptan treatment. The factors
that influenced the efficacy of tolvaptan in liver cirrhotic
patients with ascites are also analyzed.
Methods
Patients
The prospective cohort enrolled 249 cirrhotic patients
with ascites from three clinical trials, which were con-
ducted in five medical centers between 2008 and 2012
(Fig. 1). The patients enrolled in three clinical trials were
divided into two groups according to receiving tolvaptan
(7.5 mg/day to 15 mg/day) or placebo for 7 days. The
followings were a brief clinical trial descriptions. The
first clinical trial performed from May 5, 2008 to July 7,
2009 was a multicenter, randomized (1:1), double-blind,
placebo-controlled, which was designed to evaluate the
efficacy and safety of the tolvaptan in patients with
non-hypovolemic, and non-acute hyponatremia (Clini-
calTrials.gov ID:NCT00664014). Cirrhotic patients with
hyponatremia, defined as serum sodium< 135 mmol/L,
were hospitalized to receive drug administration. They
received 15 mg/day tolvaptan or placebo for the first
4 days. After 4 days, the dose was increased to
30 mg/day and 60 mg/day in the patients whose
serum sodium levels did not respond. The remaining
patients remained on the same dosage as on days 1–4
until the 7th day.. The second clinical trial, which
was performed from 2009 to 2010, was a multicenter,
open-label, double-blinded, and placebo-controlled de-
sign (ClinicalTrials.gov ID:NCT01349335) [10]. The
aim of the trial was to evaluate the effect of tolvaptan
in cirrhotic patients with ascites. The patients en-
rolled in this trial had insufficient response to com-
bination diuretics treatment (furosemide ≥40 mg/day
and spironolactone ≥20 mg/day; or furosemide
≥20 mg/day and spironolactone ≥40 mg/day). Patients
were randomly assigned to three groups (1:1:1) receiv-
ing placebo, tolvaptan 15 mg/day and tolvaptan
30 mg/day for 7 days, respectively. The third clinical
trial, which was performed between October 5, 2010
and January 20, 2012, was a multicenter randomized,
double-blind, and placebo-controlled study (Clinical-
Trials.gov ID:NCT01349348). This trial evaluated the
efficacy and safety of tolvaptan in cirrhotic patients
with ascites. Patients who had insufficient response to
combination therapies of diuretics were treated with
tolvaptan 7.5 mg/day, tolvaptan 15 mg/day or placebo
(1:2:1) for 7 days, respectively. Patients were followed
up for 6 months after treatment. The endpoints of
the study were (1) survival of patients and (2) re-
solved serum sodium levels. Normal serum sodium
was defined as serum sodium concentration between
135 and 155 mmol/L. Mild, moderate and severe
hyponatremia were considered when levels of serum
sodium between 130 and 135 mmol/L, 125 and
Fig. 1 The flow chart of patients eligibility of the clinical trial
Wang et al. BMC Gastroenterology  (2018) 18:137 Page 2 of 8
130 mmol/L, and less than 125 mmol/L, respectively
(Table 1). “Resolved serum sodium” was defined as a
patient with hyponatremia before treatment restoring
levels of serum sodium to between 135 and 155 mmol/L
after treatment.
Decompensated cirrhotic patients were enrolled ac-
cording to the following criteria: (1) aged between 18
and 75 years, (2) definite history of cirrhosis, (3) signs
and symptoms of decompensated cirrhosis, such as spleno-
megaly, hypersplenism, variceal bleeding, ascites, and hep-
atic encephalopathy, (4) confirmed cirrhosis by image
measurements, i.e. B-ultrasound scanning (LOGIQ9; GE
Company, Fairfield, United States) and computerized tom-
ography (CT; GE HISPEED DXI; GE Company) and (5)
consenting to follow-up for six months.
Patients with the following diseases were excluded: (1)
type I hepatorenal syndrome, (2) nervous system dis-
eases such as Alzheimer’s disease, Parkinson’s disease,
multiple sclerosis, epilepsy, Guillain-Barré syndrome,
etc., (3) poorly controlled diabetes (fasting glucose >
220 mg/dL), (4) heart failure with ascites, (5) anuria
(urine volume < 100 mL/day), (6) dysuresia, (7) hepatic
encephalopathy ≥ Grade II, (8) hepatocellular carcinoma,
(9) chronic liver failure, (10) cerebrovascular accident
within 30 days prior to the study medication, and (11)
history of cerebral infarction or stroke.
The study protocol was performed in compliance with
the Declaration of Helsinki and approved by the Ethics
Committees of Beijing Youan Hospital affiliated to Cap-
ital Medical University. Signed informed consent was
obtained from each patient for using samples, materials
and publication.
Clinical and laboratory data
Symptoms, signs, and adverse events were recorded. Serum
markers for hepatitis B and C viruses were detected by elec-
trochemiluminescence immunoassay (Roche E170 modular
immunoassay analyzer, Roche Diagnostics, Mannheim,
Germany). Serum sodium and potassium levels, liver and
renal function, including serum alanine aminotransferase
(ALT), aspartate aminotransferase (AST), total bilirubin
(TBIL), albumin, creatinine, and urea nitrogen, were mea-
sured with an automatic biochemical analyzer (AU5400,
Olympus Company, Tokyo, Japan).
Safety
Patients were routinely monitored throughout the study.
Any occurrences of adverse events and deaths were
recorded.
Statistical analysis
Student’s t test, χ2, and Fisher’s exact test were used to test
the intergroup difference according to the types of vari-
ables. The Kaplan–Meier estimator and log-rank test were
used to calculate the survival rate. A P value less than 0.05
(two-way) was considered statistically significant.
Results
Study patients
After 6-month of follow-up, 230 patients finished the
study. Among them, 169 patients were treated with tol-
vaptan and 61 with placebo. The baseline characteristics
of the enrolled patients were shown in Table 1. Except
for age and etiology, there were no differences of demo-
graphic and clinical parameters, i.e. gender, Child-Pugh
grades, edema, levels of serum sodium, potassium and
Table 1 The baseline characteristics of the patients enrolled in
this study
Index Tolvaptan
(n = 169)
Placebo
(n = 61)
P value
Age (mean ± SD) 54.6 ± 8.58 51.6 ± 10.71 0.03
Gender (F/M) 33/136 12/49 0.98
Etiology of cirrhosis (n,%)
Hepatitis B 102 (60.3) 41 (67.3) 0.03
Hepatitis C 9 (5.3) 3 (4.9)
Alcohol liver disease 33 (19.5) 11 (18.0)
PBC 2 (1.2) 0 (0)
Mixeda 13 (7.7) 5 (8.2)
Cryptogenic 4 (2.4) 0 (0)
Othersb 6 (3.6) 1 (1.6)
Child-Pugh grade (n, %)
A (5–6) 2 (1.2) 1 (1.6) 0.36
B (7–9) 113 (66.8) 45 (73.8)
C (10–15) 54 (32.0) 15 (24.6)
Edema of lower limbs (n, %)
No 123 (72.8) 43 (70.5) 0.86
Yes 46 (27.2) 18 (29.5)
Serum sodium (mmol/L) 0.56
Median 135.8 135.0
(Min, Max) (117.2, 146.3) (124.8, 142.7)
Normal serum sodium (n, %)
(≥ 135 and < 150 mmol/L)
100 (59.2) 32 (52.5)
Mild hyponatremia (n, %)
(≥ 130 and < 135 mmol/L)
44 (26.0) 21 (34.4)
Middle hyponatremia (n, %)
(≥ 125 and < 130 mmol/L)
19 (11.2) 7 (11.5)
Severe hyponatremia (n, %)
(< 125 mmol/L)
6 (3.6) 1 (1.6)
Serum potassium (mmol/L) 4.2 ± 0.5 4.1 ± 0.7 0.98
Serum urea nitrogen (mmol/L) 5.3 ± 0.8 5.6 ± 0.8 0.93
aMixed etiology: Hepatitis B + alcoholic hepatitis, hepatitis B + primary biliary
cirrhosis (PBC), hepatitis C + alcoholic hepatitis, alcoholic hepatitis+ PBC.
PBC:primary biliary cirrhosis
bOther etiology: 3 drug-induced hepatitis, 2 cardiac disease, 2 autoimmune
liver disease
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urea nitrogen, between the two groups of patients at the
baseline of the clinical study. The mean age of patients
treated with tolvaptan and with placebo were 54 and
51 years, respectively (P < 0.05). The major etiology in
both groups was chronic hepatitis B infection (60.3% vs.
67.3%, P < 0.05).
Tolvaptan does not impact serum sodium levels of cirrhotic
patients without hyponatremia
First we investigated whether tolvaptan impacted serum
sodium levels in cirrhotic patients without hyponatre-
mia. This clinical study enrolled 132 cirrhotic patients
with normal serum sodium levels. Among these, 100 pa-
tients received tolvaptan treatment and 32 placebo
(Table 1). The dynamic alteration of serum sodium levels
in cirrhotic patients treated with tolvaptan or placebo
were shown in Table 2. Tolvaptan treatment for 7 days
increased mean values of serum sodium from 138.15 ±
2.58 mmol/L to 139.83 ± 3.32 mmol/L (P < 0.05). In the
period of follow-up levels of serum sodium in these pa-
tients decreased compared to those at the baseline (P <
0.05), however, the concentrations of serum sodium dur-
ing the follow-up still remained within the normal range:
136.88 ± 5.09 mmol/L after 3 months and 136.97 ±
6.92 mmol/L after 6 months. Placebo treatment for
7 days did not alter serum sodium levels of cirrhotic pa-
tients: 138.60 ± 2.24 mmol/L vs. 138.23 ± 2.16 mmol/L
(P > 0.05). During the follow-up, levels of serum sodium
in these patients reduced to 136.97 ± 4.18 mmol/L at
3 months and 133.18 ± 9.31 mmol/L (P > 0.05).
Tolvaptan improves serum sodium levels of cirrhotic
patients with hyponatremia
Next, we assessed the effect of tolvaptan on cirrhotic pa-
tients with hyponatremia. In this study, 69 cirrhotic pa-
tients (44 with mild, 19 with moderate and 16 with
severe hyponatremia) received tolvaptan treatment while
29 (21 with mild, 7 with moderate and 1 with severe
hyponatremia) were treated with placebo.
Tolvaptan treatment for 7 days significantly improved
levels of serum sodium of cirrhotic patients with hypo-
natremia (Table 2). Thirty-two patients (72.7%) with
mild, 10 (52.6%) with moderate and 2 (33.3%) with se-
vere hyponatremia restored serum sodium levels to nor-
mal levels. The mean value of serum sodium in mild,
moderate and severe hyponatremia patients with tolvap-
tan treatment for 7 days increased from 132.98 ± 1.31,
127.35 ± 1.17 and 120.87 ± 3.33 mmol/L to 136.59 ± 3.51,
132.29 ± 2.87 and 126.50 ± 6.61 mmol/L, respectively (P
< 0.01 for all). Three months after tolvaptan treatment,
levels of serum sodium in patients with mild, moderate
and severe hyponatremia remained at 133.78 ± 4.13,
132.24 ± 5.71 and 131.10 ± 6.15 mmol/L, respectively (P
< 0.01). At the end of follow-up, levels of serum sodium
in 23 patients with mild hyponatremia had decreased to
131.96 ± 5.29 mmol/L (P < 0.01,). However, 10 patients
with moderate and 2 with severe hyponatremia kept at
129.81 ± 7.02 and 132.30 mmol/L, higher than the base-
line levels (P < 0.01).
Placebo treatment did not alter levels of serum sodium in
patients with hyponatremia (Table 2). One patient with se-
vere hyponatremia died 2 days after hospitalization. The
mean values of serum sodium in patients with mild and
moderate hyponatremia before and after placebo treatment
were 131.96 ± 1.44 vs. 131.06 ± 4.65 mmol/L and 127.94 ±
0.92 vs. 129.20 ± 10.32 mmol/L, respectively (P > 0.05). Only
9 patients with mild and 2 patients with moderate hypona-
tremia in this group finished follow-up. The mean value of
serum sodium in patients with mild hyponatremia was
134.50 ± 6.20 mmol/L (P > 0.05 compared to the baseline).
Tolvaptan improves six-month survival of cirrhotic patients
with hyponatremia
Next, we examined the six-month survival of cirrhotic pa-
tients. First we analyzed the impact of tolvaptan treatment
on survival of cirrhotic patients without hyponatremia. Al-
though tolvaptan-treated patients showed higher six-month
survival rate than placebo-treated ones, the difference was
not statistically significant (P > 0.05, Fig. 2a). The differences
in three or six-month survival rates of cirrhotic patients
with hyponatremia between tolvaptan treated patients and
control patients were not statistically significant either (P >
0.05, Fig. 2b). Compared to patients receiving placebo, how-
ever, three or six-month survival rates in the hyponatremia
patients receiving tolvaptan increased from 75.87% (22/29)
and 68.97% (19/29) to 91.31% (63/69) and 89.94%,
respectively.
In hyponatremia patients receiving tolvaptan, survival
depended on the serum sodium responded to tolvaptan
treament or not. The three or six-month survival rates
in hyponatremia patients with restored normal serum
sodium (tolvaptan responders) reached 86.36% (38/44)
and 81.32% (36/44), whereas in those with unrestored
serum sodium levels (non-responders) were a mere 40%
(10/25) and 24% (6/25) (P < 0.05).
Notably, even in the hyponatremia patients receiving pla-
cebo, survival of the patients depended on restoring serum
sodium levels to normal during follow-up. The six-month
survival rate of patients with restored serum sodium levels
(62.5%) was significantly higher than of those without
(28.7%), P < 0.01. The Kaplan–Meier survival curves shown
that the survival of patients with resolved serum sodium
was significantly higher than of those unresolved serum so-
dium either tolvaptan or placebo treatment (Fig. 2c).
Safety assessment
No side-effects were detected during treatment and
follow-up of this study. Monitoring liver function did
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not detect any tolvaptan-associated alterations in serum
ALT and TBIL levels (data not shown).
Discussions
Hyponatremia is tightly associated with cirrhotic compli-
cations, including hepatic encephalopathy, refractory as-
cites, renal failure, spontaneous bacterial peritonitis, and
hepatic hydrothorax, and concomitant high mortality
[11]. Tolvaptan is a recently FDA approved drug used to
treat hyponatremia in cirrhotic patients. Given only sev-
eral clinical trials of tolvaptan have been published to
date [11–16], including for treatment of liver cirrhotic
patients with refractory ascites [17], the safety and effi-
cacy of this drug in cirrhotic patients are not clarified
yet. It is unknown to date whether tolvaptan treatment
improves the survival of cirrhotic patients. It is also not
clear whether tolvaptan has similar or different efficacy
in cirrhotic patients with different degree of hyponatre-
mia. A single-center retrospective study in Japan in-
cluded 95 cirrhotic patients who received tolvaptan for
ascites treatment [9]. Among patients with hyponatremia
(serum sodium level < 135 mEq/L), 60.0% achieved a
normal level after 1 week treatment, and the survival
rate was significantly higher in patients with a normal-
ized serum sodium level.
In this prospective cohort study, which comprised 249
cirrhotic patients with ascites from three clinical trials
and five medical centers, we investigated the impact of tol-
vaptan on six-month mortality of cirrhotic patients with
different levels of serum sodium. We found that low dos-
age of tolvaptan (7.5 mg/day or 15 mg/day) treatment for
7 days significantly improved six-month survival of de-
compensated cirrhotic patient with hyponatremia. Com-
pared to placebo-treated patients whose six-month
survival rate was 68.97%, 89.94% of decompensated cir-
rhotic patients with hyponatremia survived after tolvaptan
treatment. Survival in tolvaptan-treated patients was de-
termined by whether they responded to tolvapatan or not.
Hyponatremic patients who restored normal levels of
serum sodium after tolvaptan treatment (tolvaptan re-
sponders) demonstrated a six-month survival rate of
89.31%, whereas those with refractory hyponatremia
(non-responders) only had a 24% survival rate. The base-
line serum sodium levels were closely associated with the
efficacy of tolvaptan. Compared to the impressive benefit
of tolvaptan on cirrhotic patients with mild and moderate
hyponatremia whose six-month survival rate was more
than 50%, the drug seems to have limited effects on cir-
rhotic patients with severe hyponatremia. Among 6 pa-
tients with severe hyponatremia, only 2 patients survived
and maintained normal serum sodium levels 6 months
after tolvaptan treatment. The result is consistent with
two previous studies [18, 19]. It is unknown why severe
hyponatremia in cirrhotic patients is difficult to treat with
Fig. 2 Six-month survival of cirrhotic patients with ascites who received tolvaptan or placebo treatment. The Kaplan–Meier survival curves was
not statistically significant difference in patients without hyponatremia between tolvaptan and placebo treatment (P > 0.05, a), also in cirrhotic
patients with hyponatremia(P > 0.05, b).However, the survival of patients with resolved serum sodium was significantly higher than of those
unresolved serum sodium either tolvaptan or placebo treatment(P < 0.01, c)
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tolvaptan. The existence of an adaptive renal response to
chronic hyponatremia, which results in a diminished re-
sponse to a selective antagonist such as tolvaptan, might
be an explanation [20].
In contrast to its efficacy of tolvaptan in cirrhotic pa-
tients with hyponatremia, tolvaptan did not significantly
alter serum sodium concentration and improve survival
in cirrhotic patients without hyponatremia. Interestingly,
placebo-treated patients who recovered from hyponatre-
mia had significantly higher survival outcome than those
who didn’t. These results argue a crucial role of restor-
ing hyponatremia for cirrhosis recovery. More than 80%
hyponatremic patients who did not respond to tolvaptan
treatment died of hepatorenal syndrome (data not
shown). Therefore, it is very important to predicte the
therapeutic response to tolvaptan in clinical practice.
Several recent clinical studies showed that serum BUN/
Cr ratio ≥ 17.5, urine Na/K ratio < 3.09, and decreased
urinary aquaporin 2 levels were predictive of being
non-responsiveness to tolvaptan [21–23]. It is not totally
clear why a short tolvaptan administration can improve
survival in cirrhotic patients. Based on current know-
ledge, hyponatremia is the most important factors affect-
ing the prognosis of patients with cirrhosis and ascites
[2, 11]. Resolved hyponatremia may directly reduce the
risk of hepatic encephalopathy, hepatorenal syndrome
and spontaneous peritonitis in decompensated cirrhotic
patients, which may directly improve survival in patients
who respond to tolvaptan treatment [9]. This might par-
tially explain why the survival is significantly improved
in resolved hyponatremia patients following tolvaptan
treatment.
Considering the safety of patients, this clinical trial
adopted low dosages of tolvaptan. These dosages are
safe. No tolvaptan-associated side effects were reported
in this study. Notably, whether increasing dosage can
improve the efficacy of tolvaptan and thus increase re-
sponse rate or survival rates in responders should be fur-
ther investigated in the future clinical studies.
Conclusions
Taken together, we found that the six-month survival
may be improved in cirrhotic patients with hyponatre-
mia after tolvaptan short administration, particularly in
tolvaptan responders. Severity of hyponatremia in cir-
rhotic patients impacts the response of tovalptan. The
underlying mechanisms should be further investigated.
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